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Abstract
With recommended screening for hepatitis C among the 1945–1965 birth cohort and advent
of novel highly effective therapies, little is known about health disparities in the Hepatitis C
care cascade. Our objective was to evaluate hepatitis C screening rates and linkage to
care, among patients who test positive, at our large integrated health system. We used elec-
tronic medical records to retrospectively identify patients, in the birth cohort, who were seen
in 21 Internal Medicine clinics from July 2014 to June 2015. Patients previously screened
for hepatitis C and those with established disease were excluded. We studied patients’
sociodemographic and medical conditions along with provider-specific factors associated
with likelihood of screening. Patients who tested positive for HCV antibody were reviewed
to assess appropriate linkage to care and treatment. Of 40,561 patients who met inclusion
criteria, 21.3% (8657) were screened, 1.3% (109) tested positive, and 30% (30/100) com-
pleted treatment. Multivariate logistic regression showed that African American race, male
gender, electronic health engagement, residency teaching clinic visit, and having more than
one clinic visit were associated with higher odds of screening. Patients had a significant
decrease in the likelihood of screening with sequential interval increase in their Charlson
comorbidity index. When evaluating hepatitis C treatment in patients who screened positive,
electronic health engagement was associated with higher odds of treatment whereas Med-
icaid insurance was associated with significantly lower odds. This study shows that hepatitis
C screening rates and linkage to care continue to be suboptimal with a significant impact of
multiple sociodemographic and insurance factors. Electronic health engagement emerges
as a tool in linking patients to the hepatitis C care cascade.
Introduction
Hepatitis C affects 185 million people worldwide[1] and over 3.2 million Americans[2, 3]. Hep-
atitis C is associated with high morbidity, frequent complications, and a higher mortality rate
than HIV [4]. Direct-acting antivirals (DAA) can cure over 95% of hepatitis C infections
through short-course, well-tolerated regimens [5]. With DAA availability, hepatitis C
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eradication becomes dependent on optimizing screening and linkage to care [6]. Experience in
treating HIV patients has refined understanding of “linkage to care” and “care cascade” con-
cepts whereby patients are screened, treated, and followed for adherence and response [7].
These concepts are also applicable in hepatitis C care [8].
As the 1945–1965 birth cohort has the highest hepatitis C prevalence [9], the Centers for
Disease Control and Prevention and US Preventive Services Task Force recommended they
receive 1-time hepatitis C testing regardless of risk factors [10, 11]. In previous studies screen-
ing has been as low as 1%-16% in eligible patients [12] and less than half of those positive
underwent hepatitis C RNA testing [13–16], the first step in the hepatitis C care cascade. For
our large health system in southeast Michigan, we aimed to identify hepatitis C screening rates
and linkages to care in patients who test positive for hepatitis C antibody.
Materials and Methods
This retrospective cohort study identified patients born between 1945 and 1965 who were seen
at any internal medicine (IM) clinic within the Henry Ford Health System from July 1, 2014
through June 30, 2015. Based in Detroit, Henry Ford Health System serves a population of over
4 million in southeast Michigan. The study was conducted at 21 urban and suburban general
internal medicine practice clinics serving an insured population of approximately 100,000
patients. One-fourth of these clinics are part of the IM residency teaching program while the
rest are staffed by Henry Ford Medical Group physicians. All enrolled clinics included hepatitis
C antibody screening as one of the health maintenance modules in the EMR. The module
reminded age-appropriate patients, through emails, and their providers, through programmed
alerts at the time of the office visit, that they are due for screening. This was implemented 3
months prior to our study’s start date and was a part of the comprehensive health maintenance
section in the EMR. No separate educational interventions, pertinent to hepatitis C screening,
were conducted prior to or during the study period.
This study aimed to identify rates of hepatitis C screening, linkage to care, and completed
treatment in patients of the 1945–1965 birth cohort. The study was approved by the Henry
Ford Health System Institutional Review Board and the requirement for an informed consent
was waived. All patient records and pertinent information were anonymized and de-identified
prior to the analysis.
Using the electronic medical record (EMR) data repository, we identified all patients in the
birth cohort who had at least 1 IM clinic visit during the study period. Patients with previous
diagnosis of chronic hepatitis C were excluded, as were patients who had already been screened
for hepatitis C prior to their clinic visit. We identified patients’ sociodemographic factors, clini-
cal comorbidities, engagement in the EMR patient portal, as well as provider-specific factors to
assess their association with the likelihood of hepatitis C screening. We then reviewed the
charts of all patients who screened positive for hepatitis C antibody to assess for appropriate
linkage to care and treatment. The care linkage dataset contained demographic information,
dates and locations of all clinic visits, and results of laboratory studies. In assessing hepatitis C
treatment rates, we excluded patients with active drug or alcohol use as they were ineligible for
treatment due to insurance restrictions for active users.
Demographics included date of birth, gender, race, income level, and geographic site of
clinic visit. Income level was estimated based on the average household income for the patient
location according to geocode census from public census data. The history of drug use was
extracted from the medical records and was contingent on patients’ self-reporting as well as
physicians’ documentation. Electronic health engagement was defined as active subscription,
through accessing the patient portal of the EMR within the last 1 year. To assess the degree of
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liver fibrosis among patients diagnosed with hepatitis C, we used the noninvasive FIB-4 score
which combines patient’s age with biochemical values (liver enzymes and platelet counts). A
FIB-4 score of<1.45 has a negative predictive value of 94.7% for severe fibrosis while a score of
>3.25 has a positive predictive value of 82.1% for severe fibrosis [17].
Statistical analysis
We used descriptive statistics, chi-square analysis, two-sample t-tests, and Wilcoxon rank sum
tests to identify the proportion of patients screened for hepatitis C, patient and provider factors
associated with screening, hepatitis C positivity rate, and factors associated with appropriate
linkage to care among hepatitis C antibody positive patients. Categorical variables were com-
pared using chi-squared test of independence and numeric variables were compared with two-
sample t-test or Wilcoxon rank sum. We also performed a multivariate logistic regression to
analyze the odds of ever being screened and then being treated if they tested positive. Variables
significant in univariate analysis and confounders with a p-value< 0.25 were included in the
multivariable model, thereby helping to ensure adequate power and stability. On multivariate
analysis, we divided the Charlson comorbidity index into 3 categories: index scores of 4, 2–3,
and 1. All statistical tests were conducted at a two-sided significance level of 0.05.
Results
A total of 47,304 patients in the birth cohort were seen in our IM clinics during the 1-year
study period. After excluding 6743 patients who were previously screened or had established
hepatitis C disease, 40,561 patients met inclusion criteria. Of these, 8657 patients (21.3%) were
screened for hepatitis C, using HCV antibody test, and 109 (1.3%) tested positive.
Patient characteristics
Patient demographics are shown in Table 1. Patients had a mean age of 59.4 ± 5.8 years and
were primarily female (59.1%), Caucasian (50.5%) and African American (43.0%). The patients
Table 1. Birth Cohort Demographic Characteristics.
Variable Result
Age, years (± SD) 59.4 ± 5.8
Race
African American 15,154 (43.0%)
Caucasian 17,783 (50.5%)
Other 2306 (6.6%)
Gender
Male 16,585 (40.9%)
Female 23,976 (59.1%)
HIV positive 164 (0.4%)
Drug use (current or former) 1415 (3.5%)
Clinic setting
Residency teaching clinics 7148 (17.6%)
Other practice 33,413 (82.4%)
Average number of office visits in 12 months (± SD) 2.2 ± 1.6
Median household income (± SD) $52,037 ± 20,365
Average Charlson Comorbidity Index (± SD) 0.88 ± 1.5
SD = standard deviation
doi:10.1371/journal.pone.0161241.t001
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had a mean of 2.2 clinic visits (S1 Table) within the study period with 17.6% of the patients
seen in the IM residency teaching clinics. Current or previous history of drug use was reported
in 1415 patients (3.5%). Distribution of the median of median household income for the birth
cohort is shown in S2 Table.
Screening for hepatitis C
Univariate analysis results are shown in Table 2. African Americans were more likely to be screened
than Caucasians (23.3% vs. 19.8%, P< 0.001). Men were more likely to be screened than women
(22.2% vs. 20.7%, P< 0.001). Patients engaged in electronic health also had higher screening rates
(22.7% vs. 19.8%, P< 0.001). Screening was more common in patients seen in residency teaching
clinics (23.5% vs. 20.9%, P< 0.001), and screened patients had a higher mean number of visits
(2.36 vs. 2.14, P< 0.001). Patients who were screened for hepatitis C had a slightly lower, but not
statistically significant, mean Charlson comorbidity index (0.86 vs. 0.91, P = 0.88).
Multivariate logistic regression results are shown in Table 3 and all variables included in the
multivariate model are in S3 Table. These analyses reinforced that African American race
(adjusted OR [aOR] 1.34, 95% CI 1.25–1.34) and male gender (aOR 1.18, 95% CI 1.11–1.25)
were associated with higher odds of screening. Similarly, odds of screening were higher in
patients engaged in electronic health (aOR 1.24, 95% CI 1.17–1.31), those seen within a resi-
dency teaching clinic (aOR 1.20, 95% CI 1.11–1.30), and patients seen more than once in IM
clinics during the study period (aOR 1.42, 95% CI 1.34–1.51). Patients had a significant
decrease in the likelihood of screening with each sequential interval increase in their Charlson
comorbidity index (aOR 0.87, 95% CI 0.82–0.92).
Linkage to care
Of the 109 patients who tested positive for hepatitis C antibody, 5 (4.6%) had active drug or
alcohol use and were excluded from treatment analysis. Of the remaining 104 patients, 69
Table 2. Univariate analysis comparing screened versus not screened.
Variable Screened N = 8657 Not Screened N = 31,904 P-Value
Age, years (± SD) 59.5 ± 5.7 59.3 ± 5.9 0.007
Gender <0.001
Male 3684 (22.2%) 12,901 (77.8%)
Female 4973 (20.7%) 19,003 (79.3%)
Race <0.001
Caucasian 3527 (19.8%) 14,256 (80.2%)
African American 3538 (23.3%) 11,616 (76.7%)
Other 1592 (20.9%) 6032 (79.1%)
Electronic health engagement <0.001
Subscribed to patient portal 4929 (22.7%) 16,769 (77.3%)
Non-subscribers 3728 (19.8%) 15,135 (80.2%)
Clinic setting <0.001
Residency teaching clinic 1677 (23.5%) 5471 (76.5%)
Other clinics 6980 (20.9%) 26,433 (79.1%)
Drug use (current or former) 1104 (78%) 311 (22%) 0.552
Average number of office visits in 12 months (± SD) 2.36 ± 1.66 2.14 ± 1.55 <0.001
Median household income (± SD) $52,146 ± 20,766 $52,008 ± 20,256 0.89
Average Charlson Comorbidity Index (± SD) 0.86 ± 1.38 0.91 ± 1.51 0.88
SD = standard deviation
doi:10.1371/journal.pone.0161241.t002
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patients (66.4%) had quantitative hepatitis C RNA testing and 51 patients (49%) were evalu-
ated by a hepatitis C specialist (Infectious Diseases or Gastroenterologists). Baseline demo-
graphic and clinical characteristics of patients who screened positive for hepatitis C antibody
and RNA test are shown in S4 Table. A total of 30 patients completed the course of hepatitis C
treatment, 70 patients were not treated, and 4 patients did not require any therapy as they had
undetectable hepatitis C virus RNA. Table 4 summarizes the proportions of treated and
untreated patients categorized by patient characteristics. Likelihood of treatment was signifi-
cantly higher in women (42.1% vs. 22.6%, P< 0.05) but did not differ by race. There was a
trend towards a lower treatment rate in patients with income levels lower than the state’s mean
Table 3. Variables associated with hepatitis C virus screening onmultivariate analysis.
Variable Odds Ratio 95% CI P-Value
African American race 1.34 1.25–1.43 <0.001
Male gender 1.18 1.11–1.25 <0.001
Electronic health engagement 1.24 1.17–1.31 <0.001
Office visits
Setting: residency teaching clinic 1.20 1.11–1.30 <0.001
Frequency > 1 office visit 1.42 1.34–1.51 <0.001
Interval Charlson Comorbidity Index 0.87 0.82–0.92 <0.001
Drug use (current or former) 1.01 0.88–1.17 0.87
doi:10.1371/journal.pone.0161241.t003
Table 4. Univariate analysis comparing hepatitis C virus positive patients who received treatment to untreated subjects.
Variable Treated Patients N = 30 Untreated Patients N = 70 P-Value
Age, years (± SD) 62.2 ± 4.7 61.1 ± 4.7 0.28
Gender 0.04
Male 14 (22.6%) 48 (77.4%)
Female 16 (42.1%) 22 (57.9%)
Race 0.38
African American 21 (28.0%) 54 (72.0%)
Other 9 (36.0%) 16 (64.0%)
Insurance 0.03
Medicaid 2 (10.0%) 18 (90.0%)
Other Insurance Coverage 28 (35.0%) 52 (65.0%)
Electronic health engagement 0.03
Subscribed to patient portal EMR 14 (45.2%) 17 (54.8%)
Non-subscribers 16 (23.2%) 53 (76.8%)
Income 0.06
Lower than state mean household income 24 (27.0%) 65 (73.0%)
Higher than state mean household income 6 (54.5%) 5 (45.5%)
Clinic setting 0.93
Residency teaching clinic 16 (29.6%) 38 (70.4%)
Other clinics 14 (30.4%) 32 (69.9%)
Medical state
Mean Fibrosis score (FIB-4) 2.48 ± 2.15 2.37 ± 1.78 0.94
Severe Fibrosis (FIB-4 > 3.25) 6 (20.7%) 9 (14.5%) 0.46
Charlson Comorbidity Index 1.77 ± 1.01 1.46 ± 1.71 0.04
EMR = electronic medical records; SD = standard deviation
doi:10.1371/journal.pone.0161241.t004
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household income (27% vs. 54.5%, P = 0.06). Medicaid beneficiaries were significantly less
likely to be treated than Medicare and commercial insurances (10% vs. 35%, P< 0.05). Similar
to the screening rates, patients engaged in electronic health had a higher likelihood of treat-
ment (45.2% vs. 23.2%, P< 0.05).
Results of multivariate logistic regression are shown in Table 5 and all variables included in
the multivariate model in S5 Table. The multivariate model included all variables from Table 4
with a p-value< 0.25. Electronic health engagement was associated with higher odds of treat-
ments (aOR 3.89, 95% CI 1.31–11.54) while Medicaid insurance coverage was associated with
significantly lower treatment odds (aOR 0.16, 95% CI 0.16–0.97) compared to patients with
different insurance coverage.
Discussion
The hepatitis C screening rate of 21.3% and completed treatment rate of 30% for the 1945–
1965 birth cohort in the IM clinic setting continue to be suboptimal despite the current recom-
mendations. In our study Medicaid beneficiaries were significantly less likely to be treated.
Men had higher screening rates but were significantly less likely to be treated. African Ameri-
cans were more likely to be screened than Caucasians but no racial differences occurred in
treatment. Patients engaged in electronic health were the sole group significantly more likely to
be screened and treated for hepatitis C.
Our study’s screening rate was higher than rates of 4.3% [18], 12.7% [19], and 15.8% [12]
reported by studies conducted before the universal hepatitis C screening recommendations for
the birth cohort. The rate of hepatitis C virus RNA testing among patients who screened posi-
tive was comparable to reported results from other studies [13–15]. Other studies done in the
birth cohort after the Centers for Disease Control and Prevention recommendations also
reported higher hepatitis C screening rates. A New York primary care study reported improve-
ment in hepatitis C screening from 11% to 46% after instituting automatic hepatitis C testing,
but they did not report on those treated [20]. A safety-net hospital in Texas instituted an EMR-
embedded hepatitis C testing algorithm with opt-out consent plus educational interventions
for staff, leading to a 49% inpatient screening rate, but only 4% (5/129) started treatment
largely because of the high number of uninsured [21].
We analyzed our cohort to identify disparities in hepatitis C screening and treatment. Of
our 30 patients who completed hepatitis C treatment, only 2 had Medicaid. While the type of
insurance coverage did not influence the likelihood of screening, Medicaid beneficiaries were
significantly less likely to receive hepatitis C treatment, if they tested positive. Similar findings
were reported in a prospective cohort study assessing the determinants of denial of DAA pre-
scriptions in 4 Northeastern states as prescriptions were more commonly denied for patients
with Medicaid than Medicare (46% vs. 4.9%, P< 0.001, aOR = 8.97). The median time to DAA
prescription fill was also longer for Medicaid patients compared to Medicare or commercial
insurance (23 days vs. 14 days, P< 0.001) [22]. In a study conducted in Illinois, only 50% of
Medicaid patients were approved for DAA therapy, with a median provider time of 92.5 min-
utes spent to obtain prior authorization [23]. A significant interstate heterogeneity was
Table 5. Factors associated with treatment in hepatitis C virus positive patients.
Variable Odds Ratio 95% CI P-Value
Female gender 2.36 0.90–6.25 0.08
Electronic health engagement 3.89 1.31–11.54 0.01
Medicaid insurance 0.16 0.16–0.97 < 0.05
Charlson Comorbidity Index 1.10 0.78–1.56 0.58
doi:10.1371/journal.pone.0161241.t005
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observed in a systematic evaluation of state Medicaid reimbursement of hepatitis C therapies
(sofosbovir) in the United States [24]. Approximately 88% of the state Medicaid committees
included absence of active drug or alcohol use in their eligibility criteria and most states
restricted hepatitis C drug coverage to patients with advanced fibrosis or cirrhosis [24, 25].
Our patients’ income level, based on geocode estimations, had no effect on hepatitis C
screening rates. However, analysis of hepatitis C patients who received treatment showed a
trend toward a lower likelihood of treatment in patients with lower income levels. Noticeably,
89% of hepatitis C positive patients had an average household income lower than $50,000, the
estimated mean household income in the state of Michigan. This is congruent with previous
reports showing that a disproportionate number of persons living with hepatitis C in the
United States have a low income [24, 26].
Of the insured, those most likely to receive hepatitis C screening and treatment in our study
were engaged in electronic health. Our EMR includes a patient portal that links patients at mul-
tiple steps in their care cascade, from reminding patients, through emails, that they are due for
health maintenance tests, to allowing patients access to their results, to electronically schedul-
ing follow-up appointments and to communicating with their health care providers, nurses
and physicians. Our results are consistent with previous studies showing that the patient por-
tals improve clinical outcomes and disease control in multiple chronic conditions [27–29]. The
portal enhances communication between the patients and their health care providers, allowing
patients to better understand and manage their disease [30].
Despite the promising role of patient portals, research has demonstrated that patients’ elec-
tronic health engagement is largely dependent on personal factors such as age, race, income,
and educational levels [31]. This may result in exclusion of vulnerable populations with signifi-
cantly lower access. Disparities in the use of the patient portal may potentially reinforce and
amplify existing health disparities; further studies are needed to evaluate potential barriers to
electronic engagement in the underserved patient population.
As the group with the lowest income in the United States [32], African Americans also have
the highest hepatitis C prevalence at 22% [33, 34]. In our cohort African Americans were more
likely to be screened for hepatitis C. Once diagnosed, there was no difference in likelihood of
treatment between African Americans and Caucasians (28% vs. 3%, P = 0.38). Hepatitis C risk
factors and disease burden vary by ethnicity [35]. A retrospective analysis of a multicenter clin-
ical trial conducted at 118 medical centers in the United States showed that African Americans
were 65% less likely to be treated for hepatitis C compared to other races [36]. They were also
less likely to respond to traditional hepatitis C therapy (peginterferon plus ribavirin) [33, 37–
39]. The higher screening rates seen in African Americans likely reflect providers’ perception
of higher disease prevalence in this population. Similar findings were seen in a study evaluating
hepatitis C screening at 4 primary care sites in Philadelphia where African Americans without
reported hepatitis C risk factors were 54% more likely than Caucasians to be screened for hepa-
titis C [34].
Men were another group significantly more likely to be screened in our study; however, they
were less likely to be treated. When adjusting for confounders, men still had a significantly
higher screening rate, while likelihood of treatment was not different. Men may be screened
more often as they are likely perceived to be at a higher risk for hepatitis C acquisition. In the
National Health and Nutrition Examination Survey from 2003 to 2010, men were 1.7 times
more likely than women to have chronic hepatitis C infection [40].
Our study has limitations. As a retrospective chart review, the variables studied were depen-
dent on patient reporting and proper documentation. The data assessing use and sexual history
were based upon patient reporting and provider input. Additionally, income level was based on
geocoding and not on individual patient reporting. Furthermore, with the retrospective
Hepatitis C Screening and Linkage to Care
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analysis we were unable to address causality between the different variables assessed and
screening or treatment rates. Consequently, an in-depth assessment of the observed disparities
in both screening and treatment of hepatitis C is limited and will require further studies to be
better explicated. Although multiple IM clinic locations with a diverse patient population were
included in this study, all data represent a single heath care system. Furthermore, our clinic
patients are all insured and therefore we are unable to account for the likelihood of treatment
and screening among uninsured subjects.
Our study highlights multiple challenges encountered in the hepatitis C care cascade. Only
a small percentage of patients eligible for testing were screened for hepatitis C with a significant
influence of sociodemographic and provider-specific factors. Furthermore, patients who tested
positive had inadequate linkage to care, particularly Medicaid beneficiaries. Despite the recent
progress and success of hepatitis C eradication with the novel DAA therapies, successful con-
trol of hepatitis C requires further public health interventions to increase screening rates and
access to care. Our study accentuates a promising role for patient engagement in electronic
health portals as a tool in linking patients to the hepatitis C care cascade. Hence, continued
efforts are needed to increase and improve patient electronic health engagement.
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